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PathogenesisAbstract Background: MicroRNAs (miRNAs) are small non-coding RNAs, whose role in regu-
lating diverse immune functions, suggests they might play a role as biomarkers for immune medi-
ated disorders. Studies showed that miRNA-146a (miR-146a) expression is increased by
proinﬂammatory cytokines and is an important modulator of differentiation and function of cells
of innate and adaptive immunity.
Aim of the work: The current study aimed to evaluate the expression of miR-146a as a potential
biomarker for diagnosis of rheumatoid arthritis (RA) and to explore its association with disease
activity.
Subjects and methods: The study enrolled 50 Egyptian subjects divided into a patient group,
which comprised 25 RA patients, and a control group which comprised 25 healthy individuals.
The disease activity for the patients’ group was determined by simpliﬁed disease activity index.
Relative quantiﬁcation of miR-146a expression in whole blood was determined using reverse tran-
scriptase quantitative real time polymerase chain reaction.
Results: There were highly signiﬁcant statistical differences between patients and healthy con-
trols as regards miR-146a relative expression, erythrocyte sedimentation rate (ESR) and anti-
cyclic citrullinated peptide (anti-CCP) (p< 0.001). Highly signiﬁcant statistical differences
(p< 0.001) were also found between different patients’ subgroups as regards miR-146a relative
expression and ESR. miR-146a levels correlated positively with those of ESR, C-reactive protein
and anti-CCP (p< 0.001).
miR-146a illustrated best performance in diagnosing RA, showing the highest sensitivity and
speciﬁcity (96% and 100%, respectively) (AUC: 0.992 at a cut off value of P2.16) compared to
anti-CCP (sensitivity: 68%, speciﬁcity: 100% and AUC: 0.87 at a cut off value of P 22 U/ml)
and RF (sensitivity: 56%, speciﬁcity: 80% and AUC: 0.992 at a cut off value of P13 U/ml).ed Hum
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Genet (2016), http://dx.doi.org/10.1016/j.ejmConclusion: This study demonstrated that miR-146a expression was highly signiﬁcantly elevated
in whole blood of patients with RA. Its diagnostic performance was better than anti-CCP and RF
and its level of expression correlates with disease activity.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is a systemic progressive
autoimmune disease characterized by chronic inﬂammation
of the synovial tissue, which leads to irreversible joint destruc-
tion and subsequent disability [1]. Considering the variable and
heterogeneous clinical presentation of the disease, its diagnosis
is primarily based on the 2010 revised American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) classiﬁcation criteria which includes the
evaluation of several clinical and serum parameters as anti-
citrullinated protein/peptide antibodies, rheumatoid factor
(RF) and acute phase reactants [2]. Nevertheless, there is still
no speciﬁc pathognomonic test for the diagnosis and identiﬁca-
tion of at risk patients, which necessitates deﬁning new
biomarkers for RA [3].
MicroRNAs (miRNAs) are small non-coding RNAs,
whose role in regulating diverse immune functions including
B and T cell selection and maturation, suggests that they might
play a central regulatory role in immunological tolerance and
can play a potential role as biomarkers for various immune
mediated disorders [4–7]. miRNA-146a (miR-146a) was ﬁrst
described by Taganov et al. who demonstrated its increased
expression in response to stimulation with lipopolysaccharides,
and its role as a regulator of the Toll-like receptor signaling by
targeting tumor necrosis factor (TNF) receptor-associated fac-
tor 6 and interleukin-1 receptor-associated kinase 1 [8]. Other
studies showed that its expression is increased by proinﬂamma-
tory cytokines and is considered an important modulator of
differentiation and function of cells of innate and adaptive
immunity [9,10]. It has been implicated in the pathogenesis
of RA via regulation of multiple target genes linked to inﬂam-
mation and apoptosis [11]. Levels of miR-146a expression have
been investigated in synovial tissues, ﬁbroblasts [12–14],
T-cells, B-cells, IL-17 producing CD4 cells [15], peripheral
blood-derived mononuclear cells (PBMC) [14] and plasma
[13] of RA patients. However, There is conﬂicting evidence
regarding the association between the level of miR-146a and
the disease course [11].
The current study aimed to evaluate the expression of miR-
146a as a potential biomarker for diagnosis of RA using whole
blood owing to the feasibility and the minimally required
manipulation of the sampling that won’t alter the molecules
level in samples, and to explore its association with disease
activity.
2. Subjects and methods
2.1. Study design
This observational case–control study was conducted in the
period from March to August, 2015.MA et al., MicroRNA-146a expression
hg.2016.07.001The work was approved by Ain Shams University (ASU)
Ethics Committee. It was carried out in accordance with The
Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments in humans. Informed consent was
obtained from all participants.
2.2. Patients and controls
The study involved 50 Egyptian subjects, who were divided
into two groups; patients and controls.
Patient Group: Included 25 patients recruited from the
rheumatology outpatient clinic, ASU Hospitals. Patients were
included in this group after being diagnosed with RA accord-
ing to the ACR/EULAR classiﬁcation criteria [2]. Patients suf-
fering from any other autoimmune disorders, chronic illnesses
or comorbidities were excluded from the study.
Control Group: Included 25 apparently healthy individuals
whose age and sex were matched with those in the patients
group.
2.3. Data collection
Relevant sociodemographic and clinical data were collected in
a standardized collection form. Results of clinical rheumatol-
ogy examination including disease duration, number of tender
swollen joints, morning stiffness, extra articular manifesta-
tions, in addition to the simpliﬁed disease activity index
(SDAI) score [16] were recorded for each patient.
2.4. Laboratory investigations
2.4.1. Sample collection
Adequate blood samples were collected from each subject
under complete aseptic condition. The samples were divided
into two parts; one part was used for analysis of the erythro-
cyte sedimentation rate (ESR, mm/h), C-reactive protein
(CRP, mg/L), complete blood picture, RF and anti-cyclic
citrullinated peptide (anti-CCP). The other part was preserved
in tubes containing EDTA at 80 C for the relative quantiﬁ-
cation (RQ) of miR-146a expression.
2.4.2. RQ of the miR-146a expression
(a) Purification of RNA from blood: RNA was isolated from
blood using the blood MicroRNA extraction kit ‘‘miR-
Neasy Mini Kit” (Qiagen, Hilden, Germany) according
to manufacturer’s instruction. Brieﬂy, after thawing the
samples, QIAzol Lysis Reagent was added. Chloroform
was then added to the lysate to separate the aqueous
phase. Samples were then vortexed, incubated at room
temperature for 2–3 min, and centrifuged for 15 min atas a potential biomarker for rheumatoid arthritis in Egypt, Egypt J Med Hum
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the separated aqueous phase to provide appropriate
binding conditions for all RNA molecules. The samples
were then applied to the RNeasy Mini spin columns,
where the total RNA binds to the membrane and phenol
and other contaminants were efﬁciently washed away.
Samples were then eluted in the RNase-free water stored
at 20 C until further processed.
(b) Reverse transcription: miR-146a was reversibly-
transcribed using miScript II RT Kit (Qiagen, Hilden,
Germany) according to manufacturer’s protocol.
Brieﬂy, RNA template was added to the reverse tran-
scription master mix containing 5 miScript HiSpec
Buffer, 10x miScript Nucleics Mix, miScript Reverse
Transcriptase Mix, nuclease-free water in a total volume
of 20 ll. The samples were incubated for 60 min at 37 C
followed by 5 min at 95 C in conventional polymerase
chain reaction (PCR) thermal cycler (Biometera, Ger-
many) to inactivate miScript Reverse Transcriptase
Mix. The undiluted complementary DNA (cDNA) was
stored at 20 C till further processing.
(c) Quantitative real time PCR: it was performed following
a standard SYBR Green PCR protocol using miScript
SYBR Green PCR Kit (Qiagen, Germany) with the Ste-
pOne real-time PCR (Applied Biosystems, United States
of America). Each reaction mix contained 2 Quanti-
Tect SYBR Green PCR Master Mix, 10 miScript
Universal Primer, 10 miScript Primer Assay speciﬁc
for miR-146a (Qiagen, Germany), template cDNA,
and RNase-free water in a total volume of 20 ll. The
real-time cycler was programed as PCR was done as fol-
lows; enzyme activation at 95 C, followed by 40 cycles
of denaturation at 94 C for 15 s annealing at 55 C
for 30 s and extension at 70 C for 30 s. The expression
of the U6B small nuclear RNA (RNU6B) was used as
endogenous control for data normalization. The RQ
level (fold change) for miR-146a was then calculated
using the 2DDCt method [17].
2.5. Statistical analysis
Analysis of data was using SPSS (Statistical Program for
Social Science) version 20. Quantitative variables were
described as mean, standard Deviation (SD) and range. Qual-
itative variables were described as number and percentage.
Chi-square test was used to compare qualitative variables
between groups. An independent (unpaired) t-test was used
to compare quantitative variables, in parametric dataTable 1 Demographic data of the studied participants.
Characteristics Patient group (n= 25) Control gro
Age (years) 41.88 ± 11.46 41.72 ± 10
Sex
Female 24 (96%) 24 (96%)
Male 1 (4%) 1 (4%)
NS, non-signiﬁcant.
Data are presented as mean ± S.D. for continuous variables and as num
* Chi-square test.
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test was used to compare more than two groups as regards
quantitative variables (least signiﬁcant difference). Pearson’s
correlation co-efﬁcient test is a measure of the linear correla-
tion between two variables X and Y, giving a value between
+1 and 1 inclusive, where 1 is a total positive correlation,
0 is no correlation, and 1 is a total negative correlation. To
assess the diagnostic accuracy of miR-146a, a receiver operat-
ing characteristic (ROC) curve analysis was performed. The
combined ROC Curve is calculated using binary logistic
regression. The area under the ROC curve (AUC) and 95%
conﬁdence interval (CI) were then estimated to determine the
speciﬁcity and sensitivity of RA diagnosis.
Probability (p) value: p value > 0.05 was considered non-
signiﬁcant, p value < 0.05 was considered signiﬁcant and
p value < 0.001 was considered highly signiﬁcant.
3. Results
The age of participants in the patients group that ranged from
26 to 63 years (41.88 ± 11.46). There were 24 females (96%)
and one male (4%), whereas the age of controls ranged from
25 to 60 years (41.72 ± 10.93). There were also 24 females
(96%) and one male (4%). There was no statistically signiﬁ-
cant difference between both groups as regards age or sex
(Table 1).
Relevant clinical data of the patient group is summarized in
Table 2. The patient group was further subdivided according
to the disease activity by SDAI into:
(1) Remission [n= 4 (16%)].
(2) Low disease activity [n= 7 (28%)].
(3) Moderate disease activity [n= 8 (32%)].
(4) High disease activity [n= 6 (24%)].
3.1. Comparison between results of study participants as regards
miR-146a, ESR, RF, anti-CCP
There were highly signiﬁcant statistical differences between
patients and healthy controls as regards miR-146a relative
expression, ESR and anti-CCP (p< 0.001) (Table 3).
One-way ANOVA test was used to compare between the
subgroups of patients (divided according to disease activity)
regarding the same parameters. Highly signiﬁcant statistical
differences (p< 0.001) were found between different patients’
subgroups as regards miR-146a relative expression and ESR,
while levels of RF showed no statistical signiﬁcant difference
between the subgroups (p= 0.042) (Table 4).up (n= 25) Chi-square test X2/t* p-value
.93 0.051 0.960 (NS)
0.000 1.000 (NS)
ber (percentage) for categorical variables.
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Table 2 Clinical data of the patients group (n= 25).
Parameters Mean ± SD Range
Disease duration (years) 6.62 ± 5.24 1–25
SDAI 20.98 ± 14.77 2–52
CRP (mg/dl) 6.22 ± 3.64 0.5–10
ESR (mm/h) 42.80 ± 22.42 11–95
RF (U/ml) 49.88 ± 43.16 9–125
Anti-CCP (U/ml) 62 ± 54.4 10–200
SDAI, simpliﬁed disease activity index; CRP, C-reactive protein;
ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CCP,
cyclic citrullinated peptide.
4 H.M.A. Elsayed et al.miR-146a levels correlated positively with those of ESR,
CRP and anti-CCP (p< 0.001) (Fig. 1). On the other hand,
it did not correlate with either RF or disease duration (data
not shown).
3.2. Accuracy of miR-146a in diagnosing RA compared to
anti-CCP and RF
Combined ROC curve was plotted to compare the perfor-
mance of miR-146a relative expression, anti-CCP and RF in
the diagnosis of RA (Fig. 2). miR-146a illustrated best perfor-
mance characteristics showing the highest sensitivity and speci-
ﬁcity (96% and 100%, respectively) (AUC: 0.992 at a cut off
value ofP2.16) followed by anti-CCP (sensitivity: 68%, speci-
ﬁcity: 100% and AUC: 0.87 at a cut off value of P22 U/ml)
and RF (sensitivity: 56%, speciﬁcity: 80% and AUC: 0.992
at a cut off value of P13 U/ml) (Table 5).
4. Discussion
Several reports considered miR-146a an important modulator
of differentiation and function of cells of innate and adaptive
immunity, and associated it with the development and patho-
genesis of autoimmune diseases [18,10,19]. In the current
study, we evaluated its expression in RA. Statistically signiﬁ-
cant differences (p< 0.001) were observed between patients
and healthy controls as regards miR-146a relative expression.
Other researchers had studied the levels of miR-146a expres-
sion in patients with RA in different body samples. The mostTable 3 Comparison between patient and healthy controls as regar
Parameters Patients group (n = 25)
miR-146a Mean ± SD 11.52 ± 11.43
Range 1.36–51.33
ESR Mean ± SD 42.80 ± 22.42
Range 11–95
RF Mean ± SD 49.88 ± 43.16
Range 8–125
Anti-CCP Mean ± SD 62.00 ± 54.41
Range 10–200
ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CCP, cycli
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ﬁbroblasts as reported by Stanczyk et al. [12], Murata et al.
[13], Niimoto et al. [15] and Kriegsmann et al. [20]. In all of
these studies elevated levels of expression of miR-146a were
documented, suggesting its signiﬁcance as a potential biomar-
ker for RA diagnosis. However, the invasiveness of the syn-
ovectomy procedure encouraged researchers to investigate
the usefulness of other less invasive samples as indicators for
the levels of miRNA-146a expression. Pauley et al. [5] and
Abou-zeid et al. [21] reported upregulated miRNA-146a
expression in PBMCs from patients with RA than in healthy
controls, and in patients suffering from other autoimmune dis-
orders. They concluded that in patients with RA, PBMCs exhi-
bit elevated miRNA expression in a pattern similar to that
observed in RA synovial tissue. Ormseth et al. found mR-
146a levels of expression elevated in the plasma of patients
with RA [22]. In the current study we used whole blood and
so did Mookherjee and El-Gabalawy [4] who stated that whole
blood samples could accurately reﬂect miRNA levels in PBMC
and would be useful in monitoring the expression of miRNAs
as biomarkers.
Conﬂicting results were observed as regards the association
between the level of mR-146a expression and the course of the
disease. Our results showed a positive correlation between
levels of miR-146a and disease activity as demonstrated by
the highly signiﬁcant statistical difference in the levels of
miR-146a expression among different patients’ subgroups
(p< 0.001) and the highly signiﬁcant positive correlations
between miR-146a and ESR (r= 0.965, p< 0.005), CRP
(r= 0.946, p< 0.005) and anti-CCP (r= 0.715, p< 0.005).
Similarly, Nakasa et al. [14] reported a higher expression of
primary and mature mi-146a in synovial tissue of patients with
RA with a high disease activity. Pauley et al. [5] found an asso-
ciation between high miR-146a expression levels in PBMCs
and disease activity. Abou-zeid et al. [21] documented positive
correlations of miR-146a expression and disease activity repre-
sented by the values of the Disease Activity Score 28 and ESR.
On the other hand, in the study conducted by Li et al. [23]
miR-146a expression was not found to be associated with
DAI but correlated positively with tumor necrosis factor-
alpha in both peripheral blood and synovial ﬂuid. It is impor-
tant to note that all of these studies are limited by a relatively
small number of patients, and were conducted on patients
from different races and ethnicities.ds miR-146a, ESR, RF, anti-CCP.
Control group (n= 25) Independent t-test
t p-value
1.01 ± 0.48 4.592 <0.001 (HS)
0.42–2.17
12.88 ± 2.44 6.635 <0.001 (HS)
9–17
21.72 ± 24.11 2.848 0.006 (S)
7–85
13.60 ± 3.65 4.438 <0.001 (HS)
8–22
c citrullinated peptide; HS, highly signiﬁcant; S, signiﬁcant.
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Table 4 Comparison between patient subgroups as regards miR-146a, ESR, RF, anti-CCP.
Remission (n= 4) Low (n= 7) Moderate (n= 8) High (n= 6) One Way ANOVA test
F p-value
miR-146a Mean ± SD 2.87 ± 1.01 4.98 ± 0.52 9.82 ± 3.43 27.17 ± 13.81 14.068 <0.001 (HS)
Range 1.36–3.46 4.15–5.43 5.56–14.41 17–51.33
ESR Mean ± SD 16.00 ± 4.69 30.57 ± 3.82 41.50 ± 6.16 76.67 ± 12.85 60.805 <0.001 (HS)
Range 11–20 25–36 35–50 65–95
RF Mean ± SD 68.25 ± 43.87 32.29 ± 34.55 53.13 ± 47.73 53.83 ± 49.26 0.631 0.603 (NS)
Range 12–118 12–93 9–125 8–120
Anti-CCP Mean ± SD 16.25 ± 2.75 45.43 ± 68.84 65.63 ± 35.54 107.00 ± 47.32 3.255 0.042 (S)
Range 13–19 10–200 42–150 67–200
ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; HS, highly signiﬁcant; S, signiﬁcant; NS, non-
signiﬁcant.
Figure 1 Scatter diagrams showing the positive correlation between miR-146a and (a) ESR (b) CRP and (c) anti-CCP in RA patients.,
(r; Spearman correlation coefﬁcient).
Figure 2 Combined ROC curve analysis of miR-146a, RF and CRP. miR-146a showed highest area under the curve (AUC= 0.992)
followed by anti-CCP (AUC= 0.87) then RF (AUC= 0.756).
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Table 5 Performance characteristics of miR-146a expression, RF and anti-CCP in diagnosing RA.
Variables Cut oﬀ point AUC 95% CI SE Sensitivity Speciﬁcity PPV NPV Accuracy
miR-146a P2.1676 0.992 0.914–1.000 0.0129 96% 100% 100% 96.2% 99.2%
RF (U/ml) P13 0.756 0.614–0.866 0.0688 56% 80% 73.7% 64.5% 75.6%
Anti-CCP (U/ml) P22 0.870 0.744–0.948 0.0520 68% 100% 100% 75.8% 87%
RA, rheumatoid arthritis; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; AUC, area under ROC (Receiver operating characteristic)
curve; CI, conﬁdence interval; SE, standard error; PPV, positive predictive value; NPV, negative predictive value.
6 H.M.A. Elsayed et al.Despite that Churov et al. [11] concluded in a review article
that the speciﬁcity and sensitivity of a single miRNA as bio-
marker of RA is generally low, and it is preferable to use a
set of several miRNAs or the combination of miRNAs with
other parameters to get an effective diagnostic tool. In the cur-
rent study, the accuracy of miR-146a was superior to that of
RF and anti-CCP in the diagnosis of patients with RA with
an AUC of 0.992 at a cut off value ofP2.16 folds with a sen-
sitivity and speciﬁcity of 96% and 100%, respectively. Kriegs-
man et al. [20] reported that miR-146a had an AUC of 0.83.
Yet in the latter study, they were comparing RA patients with
those with osteoarthritis, not healthy controls.
A total of ﬁfty participants were included in the study,
which is considered a limitation due to their small number.
However, our ﬁndings, that proved the value of miR-146a as
a biomarker for RA, could be a guide for further wider scale
studies to help reach a better understanding of the exact role
of miRNAs in rheumatic disorders.
In this study, we intended to use and evaluate easier and
less invasive sampling procedures for better compliance.
5. Conclusion
This study demonstrated that miR-146a expression was highly
signiﬁcantly elevated in whole blood of patients with RA com-
pared to healthy controls. Its diagnostic performance was bet-
ter than anti-CCP and RF and its level of expression correlated
with disease activity.
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